FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?
Jul 2023
Episode 15: Applying CKD Interventions
Join host Dr. Peter Lin (Canadian Heart Research Centre, Canada) in conversation with Dr. Joel Topf (Oakland University, William Beaumont School of Medicine, USA) as they discuss how to combat CKD progression and the role of non-pharmacological vs pharmacological interventions. T ... Show More
15 m
<p dir="ltr">Audible Bleeding editor Wen (<a href= "https://twitter.com/WenKawaji">@WenKawaji</a>) and Matt (<a href="https://twitter.com/chia_md">@chia_md</a>) are joined by MD/PhD student Rahul Ghosh (<a href= "https://twitter.com/ghoshrx/">@ghoshrx</a>), JVS editor-in-chief D ... Show More
<p dir="ltr">Audible Bleeding editor Wen (<a href= "https://twitter.com/WenKawaji">@WenKawaji</a>) is joined by second year medical student Nishi <a href= "https://twitter.com/Nishi_Vootukuru">(@Nishi_Vootukuru</a>), third year medical student Leana Dodge (<a href= "https://twitt ... Show More
